[A23-63] Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Last updated 02.10.2023
Project no.:
A23-63
Commission:
Commission awarded on 03.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with relapsed or refractory follicular lymphoma after 3 or more lines of systemic therapy
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G22-19 | Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| G18-18 | Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| G18-19 | Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A23-66 | Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-65 | Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A24-71 | Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V | Commission completed |